Agios Pharmaceuticals Inc. (AGIO)
NASDAQ
33.09
-0.54 (-1.61%)
Real-time Data
01:30 PM
Day's Range
32.9534.09
52 wk Range
22.2446.00
Financial Statements - AGIO - Agios Pharmaceuticals Inc.
Revenue
54.02M▲ 48.0%
Net Income
-412.78M▼ 161.3%Net Margin -764.0%
EBITDA
-466.95M▲ 69.1%
Free Cash Flow
-387.29M▲ 1.1%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 54.02M | 36.49M | 26.82M | 14.24M | 0 | 0 |
| Cost of Goods | 6.34M | 4.16M | 2.88M | 1.70M | 0 | 2.80M |
| Gross Profit | 47.68M | 32.33M | 23.94M | 12.53M | 0 | 200.39M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -472.13M | -425.73M | -391.48M | -389.04M | -378.41M | -335.91M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 1.95M | 1.09B | 6.05M | 144.45M | 21.07M | - |
| Pre Tax Income | -413.79M | 717.96M | -352.08M | -231.80M | -356.51M | -329.30M |
| Income Tax | -1.01M | 44.24M | - | - | - | - |
| Net Income | -412.78M | 673.72M | -352.08M | -231.80M | 1.60B | -327.37M |
| EPS Basic | -7.12 | 11.86 | -6.33 | -4.23 | 26.55 | -4.74 |
| EPS Diluted | -7.12 | 11.64 | -6.33 | -4.23 | 26.55 | -4.74 |
| Basic Shares Outstanding | 57.97M | 56.80M | 55.65M | 54.78M | 60.44M | 68.99M |
| Diluted Shares Outstanding | 57.97M | 56.80M | 55.65M | 54.78M | 60.44M | 68.99M |
| Ebit | -472.13M | -425.73M | -391.48M | -389.04M | -378.41M | -335.91M |
| Ebitda | -466.95M | -1.50B | -384.86M | -518.18M | -375.81M | -326.12M |
| Net Income Continuous Operations | -412.78M | 673.72M | -352.08M | -231.80M | -356.51M | -329.30M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
